Table GPS-13. Last month prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)

Country		Geographical area	Year	Reference	Age range young adults	Sample size young adults	Cannabis (%)	Cocaine (%) (1)	Amphetamines (%) (2)	Ecstasy (%) (3)	LSD (%)
Belgium		National	2004	(6)	15-34		7.6
Bulgaria		National	2005	(1)	18-34	433	1.7	0.4	0.4	1.1	0.4
Czech Republic		National	2004	(2)	18-34	1414	9.8	0.1	0.5	2.3	0.2
Denmark		National	2005	(4)	16-34	3583	5.9	1	0.6	0.2	0
Germany		National	2006	(7)	18-34	3306	5.5	0.4	1	0.5	0.1
Estonia		National	2003	(2)	15-34	646	3.3	0	0.8	0.9	0
Ireland		National	2006-07	(5)	15-34	1989	4.2	1	0.2	0.6	0.1
Greece		National (except Aegean and Ionian Islands)	2004	(3)	15-34	2620	1.5	0.1	0.1	0	0
Spain		National	2005-06	(6)	15-34	14699	15.5	2.8	0.9	1.2
France		National	2005	(6)	15-34	10855	9.8	0.5	0.1	0.3	0.1
Italy		National	2005	(3)	15-34	16552	8.8	1.2	0.2	0.3	0.3
Cyprus		National	2006	(1)	15-34	1753	2.1	0.4	0.3	0.8	0.3
Latvia		National	2003	(1)	15-34		3.7	0.1	1.1	0.6	0.6
Lithuania		National	2004	(1)	15-34	1814	1.5	0.2	0.2	0.4	0.1
Hungary		National	2003	(2)	18-34	2319	2.8	0.4	0.8	0.8	0.3
Malta		National	2001	(1)	18-34	640
Netherlands		National	2005	(3)	15-34		5.6	0.4	0.4	0.8	0
Austria		National	2004	(1)	15-34	1754	6.4	0.5	0.6	0.8	0.2
Poland		National	2006	(2)	15-34	2031	1.9	0.1	0.3	0.3	0
Portugal		National	2007	(2)	15-34	4765	4.5	0.6	0.2	0.4	0.1
Romania		National	2004	(1)	15-34
Slovakia		National	2006	(6)	15-34	556	4.2	0.4	0.4	0.1
Finland		National	2006	(7)	15-34	1387	3.5	0.3	0.6	0.2	0.1
Sweden		National	2006	(7)	16-34	14408	1.5
United Kingdom		England and Wales	2006-07	(10)	16-34	11973	9.2	2.7	1	1.8	0.2
United Kingdom		Northern Ireland	2005	(12)	16-34		6.5	0.5	0.8	1	0
United Kingdom		Scotland	2006	(15)	16-34	1115	12.6	4.1	1.5	3.3	0.4
United Kingdom		United Kingdom	2004	(13)	16-34		11.6	2.2	1	1.8	0.2
Norway		National	2004	(2)	15-34	1238	4.5	0.7	0.3	0.1	0

Notes:

 (1) Cocaine, any form. 

 (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy. 

 (3) For Spain: ecstasy and other designer drugs. 

 This table aims to provide an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey. 

 In surveys with small sample sizes results should be interpreted with caution. 

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15–64, young adults: 15–34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

 For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions. 

 See also 'General notes for interpreting data' on the Explanatory notes and help page. 

Sources:

 See Table GPS-0.  

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)